文献速递淋巴瘤

空间分辨肿瘤微环境预测复发/难治性霍奇金淋巴瘤治疗结局

Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2023-12-19

本研究对71对原发诊断与复发活检组织行成像质谱流式,计算肿瘤微环境中各细胞类型与HRS细胞的空间评分,发现CXCR5+ HRS细胞与CXCL13+巨噬细胞的空间互作轴,并建立RHL4S预后模型,可将患者分为移植后结局显著不同的高风险与低风险组,并在独立队列中验证。

要点

  • 配对诊断与早期复发样本的肿瘤微环境模式相似,而诊断与晚期复发样本的模式差异更大。
  • CXCR5+ HRS细胞与CXCL13+巨噬细胞的空间互作是复发霍奇金淋巴瘤中的突出串扰轴。
  • 基于四个空间参数(CXCR5+ HRS细胞、PD1+CD4+ T细胞、CD68+肿瘤相关巨噬细胞、CXCR5+ B细胞)的RHL4S模型可区分移植后结局显著不同的高风险与低风险组,并在独立队列中验证。

核心结论

  • 研究识别出CXCR5+ HRS细胞与表达配体的CXCL13+巨噬细胞的互作是复发霍奇金淋巴瘤中的突出串扰轴,并据此建立了适用于复发/难治性经典型霍奇金淋巴瘤活检的RHL4S预后模型。

研究设计与样本

  • 对71对原发诊断与复发活检组织行成像质谱流式(IMC),使用针对经典型霍奇金淋巴瘤生物学特异的标记面板。
  • 对肿瘤微环境中每种细胞类型计算空间评分,测量最近邻细胞与恶性Hodgkin Reed Sternberg(HRS)细胞在紧密互动范围内的距离。
  • 将空间评分作为特征构建自体干细胞移植后结局的预后模型,并在独立复发/难治性经典型霍奇金淋巴瘤队列中用多重免疫荧光试验验证。

主要发现

  • 高度多重IMC数据揭示配对诊断与早期复发/难治性经典型霍奇金淋巴瘤样本中肿瘤微环境模式相似,而配对诊断与晚期复发样本中肿瘤微环境模式差异更大。
  • 整合IMC与单细胞RNA测序数据分析识别出由CXCR5+ HRS细胞及其与肿瘤微环境中CXCL13+巨噬细胞的强空间关系所定义的独特架构。
  • 使用四个空间分辨参数(CXCR5+ HRS细胞、PD1+CD4+ T细胞、CD68+肿瘤相关巨噬细胞、CXCR5+ B细胞)建立的RHL4S预后检测有效将患者分为移植后结局显著不同的高风险与低风险组。
  • RHL4S检测在独立复发/难治性经典型霍奇金淋巴瘤队列中用多重免疫荧光试验得到验证。

关键数值与推荐

  • RHL4S预后检测基于四个空间分辨参数:CXCR5+ HRS细胞、PD1+CD4+ T细胞、CD68+肿瘤相关巨噬细胞、CXCR5+ B细胞。
  • RHL4S检测将患者分为高风险与低风险组,两组移植后结局显著不同。

临床怎么用

  • 作者认为该肿瘤微环境生物学所建立的RHL4S预后模型适用于复发/难治性经典型霍奇金淋巴瘤活检,为空间生物标志物开发开辟新途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: About a third of patients with relapsed or refractory classic Hodgkin lymphoma (r/r CHL) succumb to their disease after high-dose chemotherapy followed by autologous stem-cell transplantation (HDC/ASCT). Here, we aimed to describe spatially resolved tumor microenvironment (TME) ecosystems to establish novel biomarkers associated with treatment failure in r/r CHL. PATIENTS AND METHODS: We performed imaging mass cytometry (IMC) on 71 paired primary diagnostic and relapse biopsies using a marker panel specific to CHL biology. For each cell type in the TME, we calculated a spatial score measuring the distance of nearest neighbor cells to the malignant Hodgkin Reed Sternberg cells within the close interaction range. Spatial scores were used as features in prognostic model development for post-ASCT outcomes. RESULTS: Highly multiplexed IMC data revealed shared TME patterns in paired diagnostic and early r/r CHL samples, whereas TME patterns were more divergent in pairs of diagnostic and late relapse samples. Integrated analysis of IMC and single-cell RNA sequencing data identified unique architecture defined by CXCR5+ Hodgkin and Reed Sternberg (HRS) cells and their strong spatial relationship with CXCL13+ macrophages in the TME. We developed a prognostic assay (RHL4S) using four spatially resolved parameters, CXCR5+ HRS cells, PD1+CD4+ T cells, CD68+ tumor-associated macrophages, and CXCR5+ B cells, which effectively separated patients into high-risk versus low-risk groups with significantly different post-ASCT outcomes. The RHL4S assay was validated in an independent r/r CHL cohort using a multicolor immunofluorescence assay. CONCLUSION: We identified the interaction of CXCR5+ HRS cells with ligand-expressing CXCL13+ macrophages as a prominent crosstalk axis in relapsed CHL. Harnessing this TME biology, we developed a novel prognostic model applicable to r/r CHL biopsies, RHL4S, opening new avenues for spatial biomarker development.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Aoki T, Jiang A, Xu A, et al. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. J Clin Oncol. 2023. PMID: 38113419. doi:10.1200/JCO.23.01115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。